Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Dow Plummets as Fed Update, Jobless Data Weighs ↗
The Federal Reserve's accelerated interest rate timeline and inflation forecast is putting a damper on stocks today, with worse-than-expected weekly jobless claims only adding insult to injury. 
Via Talk Markets
Topics Economy Stocks
News headline image
Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump ↗
Midway through trading Thursday, the Dow traded down 0.35% to 33,913.86 while the NASDAQ rose 0.73% to 14,142.60. The S&P also rose, gaining 0.07% to 4,226.52. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
34 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger... 
Via Benzinga
Why CureVac's Stock Is Trading Higher Today ↗
CureVac (NASDAQ:CVAC) shares are trading higher ... 
Via Benzinga
News headline image
Why CureVac Stock Is Getting Crushed Today ↗
The biotech's COVID-19 vaccine candidate no longer appears to be viable. 
Via The Motley Fool
News headline image
Mid-Morning Market Update: Markets Mixed; Kroger Earnings Top Views ↗
Following the market opening Thursday, the Dow traded down 0.29% to 33,935.28 while the NASDAQ rose 0.34% to 14,086.74. The S&P also fell, dropping 0.01% to 4,223.07. The U.S... 
Via Benzinga
Topics Stocks
News headline image
CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis ↗
CureVac stock plummeted Thursday after its messenger RNA-based Covid vaccine failed in an interim analysis. The vaccine was 47% effective against Covid of any severity. 
Via Investor's Business Daily
News headline image
CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today ↗
CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
25 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data using Q-Sphera technology. Cellect... 
Via Benzinga
News headline image
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data ↗
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its... 
Via Benzinga
News headline image
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Unusual Options Activity Insight: CureVac ↗
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Wednesday. The stock price moved up to $99.74 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
News headline image
Moderna, BioNTech Pop Despite Mounting Pressure On Covid Vaccine Patents ↗
The World Trade Organization is moving ahead with a plan that could waive Covid vaccine patents. But vaccine stocks weren't rattled Thursday. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
75 Biggest Movers From Yesterday ↗
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade... 
Via Benzinga
News headline image
50 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates ↗
Following the market opening Tuesday, the Dow traded down 0.16% to 34,574.38 while the NASDAQ rose 0.32% to 13,926.79. The S&P also fell, dropping 0.04% to 4,224.95. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Could CureVac Be a Millionaire-Maker Stock? ↗
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in. 
Via The Motley Fool
News headline image
CureVac Appoints Klaus Edvardsen as Chief Development Officer
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed ↗
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
News headline image
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech ↗
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study ↗
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-... 
Via Benzinga
News headline image
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
What's Up WIth BioNTech Stock And CureVac Stock Today? ↗
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
News headline image
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines ↗
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
News headline image
56 Stocks Moving In Friday's Mid-Day Session ↗
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
News headline image
32 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.